
Results
45
High return on equity, past performance and sound balance sheet.
45 companies
Harmony Biosciences Holdings
Market Cap: US$2.1b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$37.93
7D
1.2%
1Y
0.5%
Global Industrial
Market Cap: US$1.3b
Through its subsidiaries, operates as an industrial distributor of various industrial and maintenance, repair, and operation (MRO) products in the United States and Canada.
GIC
US$32.84
7D
3.1%
1Y
35.9%
Applied Industrial Technologies
Market Cap: US$10.5b
Distributes industrial motion, power, control, and automation technology solutions in the United States, Canada, Mexico, Australia, New Zealand, Singapore, and Costa Rica.
AIT
US$283.73
7D
3.8%
1Y
8.1%
Pegasystems
Market Cap: US$7.1b
Develops, markets, licenses, hosts, and supports enterprise software in the United States, rest of the Americas, the United Kingdom, rest of Europe, the Middle East, Africa, and the Asia-Pacific.
PEGA
US$43.03
7D
7.9%
1Y
-16.7%
Vita Coco Company
Market Cap: US$3.3b
Develops, markets, and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific.
COCO
US$56.56
7D
-1.7%
1Y
43.5%
Market Cap: US$13.6b
Operates as a visual search and discovery platform in the United States, Canada, Europe, and internationally.
PINS
US$20.33
7D
-2.1%
1Y
-48.6%
ResMed
Market Cap: US$40.2b
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.
RMD
US$263.54
7D
4.8%
1Y
11.0%
Stride
Market Cap: US$3.7b
Provides proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally.
LRN
US$88.11
7D
2.7%
1Y
-36.6%
ACADIA Pharmaceuticals
Market Cap: US$3.9b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$22.70
7D
-8.3%
1Y
22.8%